Simulations Plus (SLP): A Defensible Tech Leader in Pharma R&D Faces Short-Term Pressures but Holds Long-Term Promise
Overview
Simulations Plus (SLP) is a recognized leader in biosimulation software and services for the pharmaceutical and biotechnology industry. It delivers advanced modeling platforms and consulting that enable drug developers to accelerate R&D, reduce costs, and enhance decision-making. With over 25 years in the field, SLP supports the drug development continuum—from early discovery to post-market medical communications—via its two main revenue segments: proprietary software (~60%) and consulting/services (~40%). Following the acquisition of Pro-ficiency, SLP is now positioned as a near end-to-end technology partner for pharma R&D and clinical operations, targeting a global clientele that includes the majority of the world's top pharma firms and regulatory agencies. Its business model boasts high gross margins, recurring revenues, and defensible market positioning in an era of rising digital and AI-driven drug discovery.